Monday, October 13, 2025

4 Dividend Stocks to Double Up on Right Now — Including United Parcel Service and Pfizer

  • Enbridge should be a great stock to own if a stock market correction is on the way.

  • Pfizer and UPS face some uncertainty but remain solid dividend stocks for the long run.

  • Verizon’s CEO change doesn’t detract from its appeal.

  • 10 stocks we like better than Enbridge ›

Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up. Stocks can also be muddling along but in a great position to benefit from changing market dynamics. Each of these scenarios can present terrific buying opportunities for investors.

Can you find examples of all of these scenarios in the market today that could appeal to income investors? Absolutely. Here are four dividend stocks to double down on right now.

Person reading newspaper with laptop and file folders nearby.
Image source: Getty Images.

Enbridge (NYSE: ENB) could be a fantastic stock to own if a stock market correction is on the way. With valuations near record highs and festering macroeconomic uncertainty, an overall market downturn might be in the cards.

However, I think Enbridge would hold up quite well in a highly volatile environment. The company’s pipelines transport around 30% of the crude oil produced in North America and 20% of the natural gas consumed in the U.S. But Enbridge has minimal exposure to commodity prices and is largely insulated from inflation.

The company is also the biggest natural gas utility in North America based on volume. This business makes Enbridge even more resilient to economic and market turbulence.

Income investors should like that Enbridge has increased its dividend for 30 consecutive years. They’ll also probably love the energy leader’s forward dividend yield of 5.7%.

It’s easy to find things to worry about with Pfizer (NYSE: PFE). However, I also think it’s easy to make too much of those concerns.

Pfizer logo.
Image source: Getty Images.

Take the Trump administration’s tariffs on pharmaceutical imports to the U.S. Pfizer will be exempt from those tariffs for the next three years thanks to its investments in U.S. expansion.

What about the patent cliff the big drugmaker faces over the next few years? It’s a legitimate concern. However, Pfizer has multiple newer products on the market with fast-growing sales that should largely offset any revenue decline resulting from its key patent expirations.

Meanwhile, Pfizer offers one of the best dividends in the entire healthcare sector (and the entire market, for that matter). Its forward dividend yield tops 6.8%. Management remains committed to maintaining and growing the dividend, too.

Source link

Latest Topics

Related Articles

spot_img